Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Carcinoma, Hepatocellular 61Stomach Neoplasms 46Carcinoma, Non-Small-Cell Lung 37Colorectal Neoplasms 24Esophageal Squamous Cell Carcinoma 19Lung Neoplasms 12Rectal Neoplasms 11Nasopharyngeal Carcinoma 11Esophageal Neoplasms 11Neoplasms 8Squamous Cell Carcinoma of Head and Neck 7Pancreatic Neoplasms 7Neoplasm Metastasis 7Cholangiocarcinoma 6Uterine Cervical Neoplasms 5Small Cell Lung Carcinoma 5Liver Neoplasms 5Triple Negative Breast Neoplasms 4Recurrence 4Endometrial Neoplasms 4Colonic Neoplasms 4Carcinoma, Renal Cell 4Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Extranodal NK-T-Cell 3Colorectal Cancer Metastatic 3Carcinoma 3Breast Neoplasms 3Advanced Solid Tumors 3Advanced Solid Tumor 3Turcot syndrome 2

Interventions

Bevacizumab 19Capecitabine 15Oxaliplatin 11Irinotecan 11Cetuximab 11Fluorouracil 10Leucovorin 8aflibercept 7Panitumumab 6trifluridine tipiracil drug combination 4Nivolumab 4sintilimab 3regorafenib 3Ipilimumab 3Vemurafenib 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Folfox protocol 2Drug Therapy 2tremelimumab 1spartalizumab 1raltitrexed 1pembrolizumab 1monoclonal antibody YYB-101 1masitinib 1irinotecan sucrosofate 1glucopyranosyl lipid-A 1folfirinox 1durvalumab 1camrelizumab 1balstilimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Colorectal Cancer Metastatic × sintilimab × Clear all
NCT07007767 2025-06-06

Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therapies)

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 2 Not yet recruiting
32 enrolled
Gastrointestinal

Colorectal Cancer Metastatic

NCT04940546 2024-12-03

Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in PMMR/MSS CRLM Patients

Sun Yat-sen University

Phase 1/2 Active not recruiting
36 enrolled
Gastrointestinal

Colorectal Cancer Metastatic

NCT06685276 2024-11-20

Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer

Chinese PLA General Hospital

Phase 2 Recruiting
46 enrolled
Gastrointestinal

Colorectal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡